[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350550-105":59,"doc-detail-350550-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","chemo-immunotherapy-a-combination-approach-for-the-treatment-of-her2-positive-breast-cancer-in-a-mouse-model-combination-approach","Chemo-Immunotherapy, a Combination Approach for the Treatment of HER2-Positive Breast Cancer in a Mouse Model - Combination Approach","","The discovery of tumor-associated antigens marked a milestone for cancer therapy because conventional radiotherapy and chemotherapy are often insufficient. HER2 functions as a tumor-associated antigen and is aberrantly expressed in breast cancer. Because monotherapies frequently fail due to resistance mechanisms, combination strategies integrating immunotherapy with conventional agents have improved efficacy. This study evaluated multiple vaccine combinations against the 4T1-HER2 xenograft in Balb/c mice, showing that triple regimens, especially Doxorubicin plus BM-DC-HER2/Neu with QS-21 and anti-PD-L1, reduced tumor size and enhanced lymphocyte activation, IFN-γ production, and HER2/Neu-specific antibody responses.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/chemo-immunotherapy-a-combination-approach-for-the-treatment-of-her2-positive-breast-cancer-in-a-mouse-model-combination-approach/350550/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/chemo-immunotherapy-a-combination-approach-for-the-treatment-of-her2-positive-breast-cancer-in-a-mouse-model-combination-approach/350550.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is HER2 targeted in this study?","Question",{"text":113,"@type":114},"HER2 is a tumor-associated antigen aberrantly expressed in breast cancer, making it a relevant target for immune-directed therapies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What combinations were tested for the vaccine strategy?",{"text":118,"@type":114},"Eight vaccine formulation groups were evaluated, including BM-DC-based and peptide-based vaccines combined with anti-PD-L1, Doxorubicin, and the QS-21 adjuvant.",{"name":120,"@type":111,"acceptedAnswer":121},"Which combination showed the strongest antitumor activity?",{"text":122,"@type":114},"The Doxorubicin + BM-DC-HER2/Neu + QS-21 + anti-PD-L1 regimen produced markedly better outcomes, including reduced tumor dimensions and stronger immune responses such as CD4+ and CD8+ activity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350550,1790162187,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nChemo-Immunotherapy, a Combination Approach for the Treatment of HER2-Positive Breast Cancer ina Mouse Model  \nCenk Serhan Özverel1  | Kubilay Doğan Kılıç2  | Yiğit Uyanikgil2  | İsmail Karaboz1 | Ayse Nalbantsoy3   \n1Department of Biology, Faculty of Science, Ege University, Izmir, Türkiye | 2Department of Histology and Embryology, Faculty of Medicine, Ege University, Izmir, Türkiye | 3Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Türkiye  \nCorrespondence: Ayse Nalbantsoy ([analbantsoy@gmail.com](analbantsoy@gmail.com); [ayse.nalbantsoy@ege.edu.tr](ayse.nalbantsoy@ege.edu.tr))  \nReceived: 30 December 2024 | Revised: 19 November 2025 | Accepted: 29 June 2026  \nKeywords: BM-DC | breast cancer | chemotherapy | combination therapy | HER2 + | immunotherapy  \nABSTRACT  \nThe discovery of tumor-associated antigens has been a significant milestone for cancer therapy as the current conventional therapies (radiotherapy, chemotherapy) were found to be insufficient in terms of cancer treatment. Human epidermal growth factor receptor (HER2) is a tumor-associated antigen, aberrantly found in various cancers, including breast cancer. Today, most treatment strategies are skewed toward combination therapies rather than monotherapies, as they have been found primarily ineffective due to patients' resistance mechanisms. A combination of multiple therapeutic approaches (passive/active immunotherapy, conventional therapies) was found to be more effective in the clinic. This study investigated various vaccine combinations against the 4 T1-HER2 xenograft model of Balb/c mice. Eight different groups of vaccine formulations were tested to find the best synergistic combination, including combinations of BM-DC-based vaccine, peptide-based vaccine, anti-PD-L1, Doxorubicin, and QS-21 adjuvant. Triple combination groups of immunotherapies exerted better activities in terms of tumor dimensions as Doxorubicin+BM-DC-HER2/Neu + QS-21 + anti-PD-L1 and Doxorubicin+HER2/Neu + QS-21 + anti-PD-L1 groups significantly decreased tumor dimensions. Similar groups also demonstrated a better stimulation of lymphocytes and IFN-γ cytokine in the flow cytometry study, inducing a HER2/Neu-specific antibody response in ELISA studies. Doxorubicin+BM-DCHER2/Neu + QS-21 + anti-PD-L1 combination demonstrated significantly higher specific cytotoxicity in lactate dehydrogenase data, as well as the CD4+ and CD8+ responses in the immunohistochemical study. In conclusion, these data indicated that the Doxorubicin+BM-DC + HER2/Neu + QS-21 + anti-PD-L1 vaccine combination synergistically generated a promising activity in terms of tumor dimension and immune response stimulation against the HER2 overexpressing breast cancer model in mice.  \n1 | Introduction  \nImmune responses to cancers are initiated upon the presence of aberrantly expressed proteins on cancer cells. A balance between immunostimulatory and immunosuppressive mechanisms tightly regulates this immune response, preventing unwanted inflammation and autoimmune disease progression [1] . The majority of cancer immunotherapies in development for breast cancer aim to modulate immune regulation, directing immune  \nresponses toward tumor-associated antigens (TAAs), especially to human epidermal growth factor receptor 2 (HER2), or combining them with immune checkpoint blockade therapeutics [1–3] . Some recent publications also combine conventional radiotherapy or chemotherapeutic drugs with these immunotherapies to overcome patients' resistance mechanisms against drugs.  \nQS-21 is a potent immunostimulant widely used in vaccine development and immunotherapies. It boosts the body's immune  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptati","cbCaihtxpVGkkFDh","https://ap.wps.com/l/cbCaihtxpVGkkFDh","pdf",2579791,12,"English","# Abstract\n## Introduction","[{\"question\":\"Why is HER2 targeted in this study?\",\"answer\":\"HER2 is a tumor-associated antigen aberrantly expressed in breast cancer, making it a relevant target for immune-directed therapies.\"},{\"question\":\"What combinations were tested for the vaccine strategy?\",\"answer\":\"Eight vaccine formulation groups were evaluated, including BM-DC-based and peptide-based vaccines combined with anti-PD-L1, Doxorubicin, and the QS-21 adjuvant.\"},{\"question\":\"Which combination showed the strongest antitumor activity?\",\"answer\":\"The Doxorubicin + BM-DC-HER2/Neu + QS-21 + anti-PD-L1 regimen produced markedly better outcomes, including reduced tumor dimensions and stronger immune responses such as CD4+ and CD8+ activity.\"}]","Chemo-Immunotherapy, a Combination Approach for the Treatment of HER2-Positive Breast Cancer in a Mouse Model - Combination Approach | PDF",1790089551,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68dcb645820b2dd116f2dfbe7d414d15.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db54c030212b12729da4f1c06771b1e4.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b258e709895feb26433814d49747d54.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0a1f7dd0a1a08a8b59d25d233dd0e3d.webp",980,1287]